Preclinical activity of SDX-7320 in mouse models of obesity and obesity-driven cancer



Peter Cornelius¹, John S. Petersen², Benjamin Mayes¹, David Turnquist³, Kimberly Sullivan⁴, Alfred Anderson-Villaluz⁴, Robert Lutz⁴, Sara Little⁵, Andrew Slee⁶, Bradley J. Carver¹, James Shanahan¹ ¹SynDevRx Inc., Cambridge, MA; ²Petersen Consulting, Acton, MA; ³Xtuit, Waltham, MA; ⁵NeoSome Life Sciences, Lexington, MA; ⁶Cove Bioconsultants, Shrewsbury, MA

Introduction

Cancer patients who are obese face a greater risk of dying from cancer compared to non-obese patients (Calle, 2003). Excess visceral adiposity is believed to contribute to metastasis and progression of cancer via multiple mechanisms: increased secretion of the adipose tissue hormone leptin, decreased secretion of adiponectin, increased production of estrogen in adipose tissue, and elevated insulin (secondary to peripheral insulin resistance) as well as the local effects of inflammatory cytokines (Gucalp, 2016).

Small molecule inhibitors of methionine aminopeptidase type 2 (MetAP2) have previously demonstrated clinical activity in cancer patients (Kudelka, 1998; Herbst, 2002) as well as in obesity/type 2 diabetes (Hughes, 2013; Kim, 2015). However, development of some small molecule MetAP2 inhibitors has been hampered by CNS toxicity (Bhargava, 1999).

SDX-7320 is a copolymer-drug conjugate of a novel fumagillin-derived MetAP2 inhibitor (SDX-7539) attached via a cleavable amino acid linker to a hydroxypropylmethacrylamide (HPMA) backbone, intended to limit CNS penetration and therefore reduce CNS toxicity. SDX-7320 is currently being evaluated in a Phase I trial of patients with solid tumors (NCT02743637).

Materials & Methods

Binding of test articles to recombinant, human MetAP2 was measured using a custom ELISA, based on a previously published example (Bernier, 2004). This assay measured the ability of test articles to compete for binding of a custom, biotinylated, fumagillin derivative (SDX-9280) to MetAP2. Proliferation of human umbilical vein endothelial cells (HUVECs) was measured using CellTiter 96® AQ_{ueous} One Solution (Promega) after incubating cells with test compounds for 72 hours in culture medium containing 2% fetal bovine serum.

Male C57Bl/6 mice (Taconic) were made obese by feeding a high-fat diet (60 % calories from fat/21% calories from sucrose) for >12 weeks until their average weight was >40 grams. SDX-7320 or vehicle (5% mannitol/water) was dosed subcutaneously (s.c.) every 4 days (Q4D) for 28 days (total of 8 doses), Intraperitoneal glucose tolerance tests (IPGTT) were carried out in the AM (day 24), after 2 hours of food deprivation by injecting dextrose (1 g/kg) into the intraperitoneal cavity at t = 0. Blood samples were obtained via the submandibular gland at the indicated times for measurement of blood glucose.


B16F10 melanoma cells were injected s.c. into C57Bl/6 mice (Jackson Lab) made obese by feeding a high fat diet (D12492, Research Diets) until their average weight was >40 g, as well as into age-matched lean mice (fed D12450J, Research Diets). Treatment with SDX-7320 (s.c., Q4D, total of six doses) was initiated when tumors reached an approximate volume of 100 mm³.

Female C57Bl/6 mice were surgically ovariectomized at six weeks of age (Jackson Lab) and following recovery were placed upon either a high-fat or lowfat diet as described above. EO771 cells (50,000; from CH3 Biosystems) were injected into the fourth mammary gland and followed until tumors reached approximately 50 mm³ at which time treatment with SDX-7320 was initiated (s.c., Q4D, total of four doses).

Bernier. (2004), PNAS, 10768-73.

References

Bhargava, P. (1999), Clinical Cancer Research, 5: 1989–1995. Calle, E. (2003), New England Journal of Medicine, 348: 1625-38. Gucalp, A. (2016), Seminars in oncology, 43: 154-160. Herbst, RS. (2002), J. Clin. Oncol. 20: 4440-7. Hughes, T. (2013), Obesity, 21: 1782-1788. Kim, D. (2015), Obesity and Metabolism, 17: 566-572. Kudelka, A. (1998), New Eng J Med, 338(14): 991.



Poster #4919